TELA Bio, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2026, TELA Bio, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “ Special Meeting ”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstandin
TELA Bio has regained compliance with Nasdaq's minimum bid price requirement, according to a notification received on Oct 5, 2026. The company's common stock continues to trade under the symbol TELA. This compliance ensures TELA Bio's continued listing on the Nasdaq Global Market.
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, TELA Bio, Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq L
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning TELA (TELA Bio, Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent TELA coverage spans corporate actions, regulation and insider activity.
In the last 30 days, TELA insiders filed 4 SEC Form 4 transactions — 4 purchases ($167K) and no sales. The most active reporter was Capper Joseph H with 4 filings.
Regaining compliance removes delisting risk and may support the share price.
The compliance regain removes delisting risk for TELA Bio.
Regaining compliance eliminates a negative catalyst and may support price appreciation.
The clearance enables commercial launch of Liora, expanding TELA Bio's product portfolio and market addressable size.
Positive regulatory approval likely lifts share price as the product expands market addressable opportunity.
AlphAI scores every news story that mentions TELA with an AI model for sentiment and relevance, and aggregates insider trades from TELA Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2026, TELA Bio, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “ Special Meeting ”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstandin
1 min readTELA Bio has regained compliance with Nasdaq's minimum bid price requirement, according to a notification received on Oct 5, 2026. The company's common stock continues to trade under the symbol TELA. This compliance ensures TELA Bio's continued listing on the Nasdaq Global Market.
1 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, TELA Bio, Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq L
1 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TELA Bio Announces 510(k) Clearance for Liora TM Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissu
2 min readTELA Bio (NASDAQ: TELA) received FDA 510(k) clearance for its Liora Monofilament Scaffold, a resorbable surgical mesh for soft tissue reinforcement. The product, developed in-house, expands the company's portfolio and market presence. Details will be discussed during the upcoming Q3 earnings call in November.
2 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, TELA Bio, Inc. (the “ Company ”) entered into a Limited Consent to Credit Agreement and Guaranty (the “ Limited Consent ”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral ag
1 min readCapper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.18 ($1.17–$1.22) across 2 trades over 2026-09-16 to 2026-09-17.
1 min readCapper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.05 ($1.02–$1.06) across 2 trades over 2026-09-14 to 2026-09-15.
1 min readTELA Bio (TELA) seeks shareholder approval for a reverse stock split (1-for-5 to 1-for-15) to meet Nasdaq's $1 minimum bid price requirement after receiving a deficiency notice. The company's stock closed at $0.79 on September 1, 2026, and a split would reduce shares outstanding from 45.1 million. The vote is scheduled for October 8, 2026, with a record date of September 8, 2026.
2 min readTELA Bio CEO Heather Getz bought 12,500 shares at $0.6649 each, totaling $8,311. She now holds 532,500 shares. TELA's stock has gained 15.5% in a week but is down 54% year-over-year. InvestingPro values the stock at $1.06. Q2 earnings missed expectations, with a loss of $0.20 per share and revenue of $19.3M. The company withdrew 2026 revenue guidance but noted gross margin improvements and growth in some segments.
2 min read
